# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cassava Sciences is cooperating with DOJ and SEC investigations involving its Alzheimer's drug simufilam. An internal commi...
Jones Trading analyst Soumit Roy downgrades Cassava Sciences (NASDAQ:SAVA) from Buy to Hold.
DOJ Indicts Dr. Hoau-Yan Wang For Allegedly Defrauding NIH With False Research Data; Wang Previously Served As Scientific Advis...
HC Wainwright & Co. analyst Vernon Bernardino downgrades Cassava Sciences (NASDAQ:SAVA) from Buy to Neutral.
Cassava Sciences, Inc. (NASDAQ:SAVA), reported it has learned today that a federal grand jury returned an indictment charging H...